Satellos Bioscience Past Earnings Performance
Past criteria checks 0/6
Satellos Bioscience's earnings have been declining at an average annual rate of -35.1%, while the Biotechs industry saw earnings growing at 13.8% annually. Revenues have been growing at an average rate of 114.6% per year.
Key information
-35.1%
Earnings growth rate
-4.5%
EPS growth rate
| Biotechs Industry Growth | 51.1% |
| Revenue growth rate | 114.6% |
| Return on equity | -39.1% |
| Net Margin | n/a |
| Last Earnings Update | 31 Dec 2023 |
Revenue & Expenses BreakdownBeta
How Satellos Bioscience makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -16 | 7 | 0 |
| 30 Sep 23 | 0 | -14 | 6 | 0 |
| 30 Jun 23 | 0 | -13 | 6 | 0 |
| 31 Mar 23 | 0 | -11 | 5 | 0 |
| 31 Dec 22 | 0 | -11 | 5 | 0 |
| 30 Sep 22 | 0 | -9 | 4 | 0 |
| 30 Jun 22 | 0 | -18 | 4 | 0 |
| 31 Mar 22 | 0 | -17 | 3 | 0 |
| 31 Dec 21 | 0 | -16 | 3 | 0 |
| 30 Sep 21 | 0 | -13 | 2 | 0 |
| 30 Jun 21 | 0 | -2 | 1 | 0 |
| 31 Mar 21 | 0 | -2 | 1 | 0 |
| 31 Dec 20 | 0 | -2 | 1 | 0 |
| 31 Dec 19 | 0 | -2 | 1 | 0 |
Quality Earnings: MSCL is currently unprofitable.
Growing Profit Margin: MSCL is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: MSCL is unprofitable, and losses have increased over the past 5 years at a rate of 35.1% per year.
Accelerating Growth: Unable to compare MSCL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MSCL is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: MSCL has a negative Return on Equity (-39.06%), as it is currently unprofitable.